Thursday, June 6, 2019

Why is Parkinson"s disease on the rise?

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two



Parkinson's is the world's fastest growing neurological disorder. On average, Parkinson's-dementia sets in 8 years after diagnosis. Learn of strategies & challenges against an impending pandemic. 




Amsterdam, NL - For most of human history Parkinson's disease (PD) has been a rare disorder. However, demography and the by-products of industrialization are now contributing to an impending Parkinson's pandemic, according to experts writing in a supplement to the Journal of Parkinson's Disease. They say that this pandemic can be addressed by the Parkinson's community forming a "PACT" to prevent the disease, advocate for policies and resources aimed at slowing its spread, care for all those affected, and treat with effective and novel therapies. 

Fastest Growing Neurological Disorder

Neurological disorders are now the leading cause of disability globally, and the fastest growing neurological disorder in the world is PD, a slowly progressive disorder that affects movement, muscle control, and balance.
  • In 1855, forty years after Dr. James Parkinson first described the condition, approximately 22 people of 15 million in England and Wales died of PD.
  • In 2014, roughly 5,000 to 10,000 individuals of 65 million in the UK died of PD.
  • From 1990 to 2015, the number of people with PD doubled worldwide to over six million.
  • Driven principally by aging, this number is projected to double again to over 12 million by 2040.
  • Additional factors, including increasing longevity, declining smoking rates, and increasing industrialization, could raise the burden to over 17 million.

We Can Truly Talk About a Pandemic



IMAGE
IMAGE: Projected global burden of Parkinson's disease accounting for changes in aging, longevity, smoking rates, and industrialization, 1990-2040.
IMAGE CREDIT: Department of Neurology and Center for Health and Technology, University of Rochester Medical Center, Rochester, NY, USA
"By 2040, we can truly talk about a pandemic that will result in increased human suffering, as well as rocketing societal and medical costs. How can the community be made aware of this scenario and implement changes in research priorities and care programs to lessen the burden of the upcoming pandemic?" cautioned Patrik Brundin, MD, PhD, Van Andel Research Institute, Grand Rapids, MI, USA, Editor-in-Chief of the Journal of Parkinson's Disease. 

According to lead author Ray Dorsey, MD, from the Department of Neurology and Center for Health and Technology, University of Rochester Medical Center, Rochester, NY, USA, "The tide of PD is rising and spreading. PD exacts an enormous human toll on those with the disease and those around them. The strain of caregiving has adverse health consequences of its own. The economic costs of PD are also substantial, poised to grow, and at least in the US, overwhelmingly directed at institutional care, which few desire."

Unprecedented Rise

The incidence of PD increases with age and the world's population is aging, as the number and proportion of individuals over 65 is rapidly growing. The combined result of these two factors is an unprecedented rise in the number of people with PD. 

Independent of PD, global life expectancy has increased by six years in the last two decades. This will likely increase the number of individuals with advanced PD who are more difficult to treat and can have limited access to care. Numerous studies have found that the risk of PD decreases among smokers by approximately 40%. If the association is causal, which remains to be determined, decreasing smoking rates could lead to higher rates of PD.

Unbridled Activism, Effective Therapies, New Models

Finally, the by-products of industrialization may be contributing to the rising rates of PD. Specific pesticides, solvents, and heavy metals, have been linked to PD - exposure to these agents is preventable. 

"In the past century, society has successfully confronted pandemics of polio, breast cancer, and HIV to varying degrees. Central to the success of these efforts was unbridled activism," stated Dr. Dorsey. Following these examples, the authors propose that the Parkinson's community form a "PACT" to prevent, advocate for, care, and treat the disease through understanding the root causes (environmental, genetic, and biological), expanding new care models that seek to bring expert care to all, and developing new highly effective therapies. The most effective therapy (levodopa) is now fifty years old.

Preventable & Not Inevitable

"We hope that this article will raise awareness of the challenge and form the basis for a community-led response to address one of the great health challenges of our time," added co-author and Associate Editor of the Journal of Parkinson's Disease Bastiaan R. Bloem, MD, PhD, from the Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, The Netherlands. 

"The PD pandemic is preventable, not inevitable," conclude the authors. 


REFERENCES:
  • "The Emerging Evidence of the Parkinson Pandemic," by E. Ray Dorsey, MD; Todd Sherer, PhD; Michael S. Okun, MD; and Bastiaan R. Bloem, MD, PhD (DOI: 10.3233/JPD-181474) published in the Journal of Parkinson's Disease, Volume 8, Supplement 1 by IOS Press.
  • SUPPLEMENT TO THE JOURNAL OF PARKINSON'S DISEASE:
    The Journal of Parkinson's Disease published a special issue in 2017 to commemorate the 200th anniversary of James Parkinson's "Essay on the Shaking Palsy," and we highlighted eight of the most important advances in Parkinson's research over the past 60 years. As we were working on that special issue, we commented on how the pace of Parkinson's research has accelerated remarkably. We speculated that there would be more advances in the treatment and care of Parkinson's disease during the coming 20 years than were evident during the preceding 200 years. Thus, the idea of a collection of short, forward-looking, and visionary articles was born. Eventually, we identified 19 topics for articles, and we are very excited about the outcome. In 1964 Bob Dylan sang "the times they are a changin';" this special supplement clearly shows that the field of Parkinson's is no exception.
SOURCES:

Sunday, June 2, 2019

How light improves Alzheimer's life

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

American Academy of Sleep Medicine:

sleep education patient resource information

Light therapy for Alzheimer's increases sleep quality, efficiency and duration, according to an important study. 4 weeks of light therapy also significantly reduced depression and agitation. Learn how. 




A key study offers an easy-to-do care tip. Research suggests that light treatment, tailored to increase circadian stimulation during the day, may improve sleep, depression and agitation in people with Alzheimer's and related dementia.

Light is Simple, Inexpensive, Non-pharmacological

Results show that exposure to the tailored light treatment during daytime hours for four weeks significantly increased sleep quality, efficiency and total sleep duration. It also significantly reduced scores for depression and agitation. 

Boosting Daytime Light Levels

"It is a simple, inexpensive, non-pharmacological treatment to improve sleep and behavior in Alzheimer's disease and dementia patients," said principal investigator Mariana Figueiro, PhD, associate professor and Light and Health program director of the Lighting Research Center at Rensselaer Polytechnic Institute in Troy, New York. "The improvements we saw in agitation and depression were very impressive." 

 Therapy lights are easy to find at places such as:


There are many ways to boost light levels during waking hours in order to correct changes in the circadian rhythm of people with Alzheimer's. The following video illustrates state-of-the-art LED lighting for the home. A discussion of the Alzheimer's / Sleep / Lighting study continues below the video. 


Dr. Figueiro's research abstract was published in an online supplement of the journal Sleep and was presented in Minneapolis, Minnesota, at the 28th annual meeting of the Associated Professional Sleep Societies LLC.

Light Exposure During the Day

The pilot study involved 14 nursing home patients with Alzheimer's disease and related dementia. A light source producing low levels of 300 to 400 lux of a bluish-white light with a color temperature of more than 9000 K was installed in the residents' rooms. Light exposure occurred during daytime hours for a period of four weeks. Light-dark and activity-rest patterns were collected using a calibrated instrument prior to and after the lighting intervention. Measures of sleep quality, depression and agitation also were collected using standardized questionnaires.

Figueiro added that the improvement in sleep quality also was associated with other noticeable behavioral changes.

"Subjective reports by the nursing staff were that the patients were calmer, eating better and their overall behavior was more manageable," she said.

Second Sleep & Lighting Study

A second "Tailored Lighting Intervention for Alzheimer's and Sleep" study confirmed these results. While all measures improved, the most significant improvement was seen in sleep quality. 

"Here we show that if the stimulus (light dose) is carefully delivered and measured, it can have a strong impact on sleep, depression and agitation," said Dr. Figueiro. "Depression was a secondary measure, and I was pleasantly surprised by the positive impact of the light treatment on depression scores." 

The study involved 43 subjects diagnosed with Alzheimer's disease and related dementias who were exposed to an active and inactive tailored lighting intervention for successive 4-week periods, spaced by a 4-week washout period. The lighting intervention was added to spaces in which patients spent most of their waking hours and was energized from wake time until 6 p.m. Calibrated personal light meters monitored exposures. Measures of sleep disturbances (Pittsburgh Sleep Quality Index), mood (Cornell Scale for Depression in Dementia) and agitation (Cohen-Mansfield Agitation Index) were collected at baseline and during the last week of the intervention. 




REFERENCE: SOURCE:
  • American Academy of Sleep Medicine:
    Established in 1975, the American Academy of Sleep Medicine (AASM) improves sleep health and promotes high quality patient centered care through advocacy, education, strategic research, and practice standards. With about 9,000 members, the AASM is the largest professional membership society for physicians, scientists and other health care providers dedicated to sleep medicine. For more information, visit http://www.aasmnet.org.
SUPPORT:
  • The research was supported by funding from the National Institute on Aging (NIA) within the National Institutes of Health (NIH).

Friday, May 24, 2019

Another reason to eat chocolate

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Related image
Loma Linda University Health

New studies show dark chocolate improves memory & mood, boosts immunity and reduces stress as well as inflammation. 


LOMA LINDA, CA — Findings from two studies show that consuming dark chocolate that has a high concentration of cacao (minimally 70% cacao, 30% organic cane sugar) has positive effects on:
  1. Stress levels
  2. Inflammation
  3. Mood
  4. Memory
  5. Immunity.

Effects of a Regular-Sized Chocolate Bar

“For years, we have looked at the influence of dark chocolate on neurological functions from the standpoint of sugar content - the more sugar, the happier we are," said Dr. Lee Berk. 

While it is well known that cacao is a major source of flavonoids, this is the first time the effect has been studied in human subjects to determine how it can support cognitive, endocrine and cardiovascular health. 

Lee S. Berk, DrPH, , served as principal investigator on both studies. Dr. Berk is associate dean of research affairs, School of Allied Health Professions and a researcher in psychoneuroimmunology and food science from Loma Linda University.

"Positive Impact"

Berk added, "This is the first time that we have looked at the impact of large amounts of cacao in doses as small as a regular-sized chocolate bar in humans over short or long periods of time, and are encouraged by the findings. These studies show us that the higher the concentration of cacao, the more positive the impact on cognition, memory, mood, immunity and other beneficial effects.” 

The flavonoids found in cacao are extremely potent antioxidants and anti-inflammatory agents, with known mechanisms beneficial for brain and cardiovascular health. The following resultswere presented in live poster sessions during the Experimental Biology 2018 meeting.

Two Studies on Dark Chocolate with 70% Cacao

These results were based on two important studies:
Berk said the studies require further investigation, specifically to determine the significance of these effects for immune cells and the brain in larger study populations. Further research is in progress to elaborate on the mechanisms that may be involved in the cause-and-effect brain-behavior relationship with cacao at this high concentration.

SOURCE:
  • Loma Linda University Health
    Loma Linda University Health includes Loma Linda University's eight professional schools, Loma Linda University Medical Center's six hospitals and more than 900 faculty physicians located in the Inland Empire of Southern California. Established in 1905, Loma Linda University Health is a global leader in education, research and clinical care. It offers over 100 academic programs and provides quality health care to over 40,000 inpatients and 1.5 million outpatients each year.

Wednesday, May 22, 2019

Reason why a dementia drug also is a blood pressure blood drug

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two



Georgetown University Medical Center

Top researchers show the generic drug candesartan (brand name: ATACAND®) may not only slow progression of Alzheimer’s, but also prevent or delay its development. See how. 




WASHINGTON  — In laboratory neuronal cultures, an FDA-approved drug used to treat high blood pressure reduced cell damage often linked to Alzheimer’s disease, say researchers at Georgetown University Medical Center (GUMC) and the National Institutes of Health.
They say their work, published online in the journal Alzheimer's Research and Therapy, provides information supporting the potential effect of the generic drug candesartan (brand name: ATACAND®) — as well as other Angiotensin receptor blockers (ARBs) for the early treatment of Alzheimer’s disease.
“Our findings make sense in many ways,” says the study’s senior author Juan M. Saavedra, MD, from GUMC’s Department of Pharmacology and Physiology.  “Hypertension reduces blood flow throughout the body and brain and is a risk factor of Alzheimer’s disease. Previous epidemiological studies found that Alzheimer’s progression is delayed in hypertensive patients treated with ARBs.”
Using neuronal cultures, the researchers explored the action of candesartan on the neurotoxic effects of exposure to excessive glutamate, a demonstrated injury factor in the early stages of Alzheimer’s disease.
The scientists found that candesartan prevented glutamate-induced neuronal death. They conducted in-depth gene analyses of the laboratory results, demonstrating that candesartan prevented neuronal inflammation and many other pathological processes, including alterations in amyloid metabolism, a hallmark of Alzheimer’s disease.
The study’s first author, Abdel G. Elkahloun, PhD, from the Comparative Genomics and Cancer Genetics Branch of the National Human Genome Research Institute, then compared gene expression in the neuronal cultures with published gene databases of autopsy samples from Alzheimer’s disease patients. “The correlations were impressive — the expression of 471 genes that were altered by excess glutamate in our cultures were also altered in brain autopsy samples from patients who suffered from Alzheimer’s disease. Candesartan normalized expression of these genes in our cultures,” Elkahloun says.
“We hypothesize that candesartan, or other members of the ARB group, may not only slow progression of Alzheimer’s but also prevent or delay its development,” Saavedra says.
The researchers say this work has immediate translational value, supporting testing candesartan, or other ARBs, in controlled clinical studies on patients at early stages of Alzheimer’s disease. 
MORE INFORMATION:Roman Hafko, PhD, formerly of the National Institute of Mental Health, also contributed to this work and is an author of the paper.
The work was supported by grants from the National Institutes of Health including the National Human Genome Research Institute (MD 20892) and the National Institute of Mental Health (MH 002762-16). The authors report having no personal financial interests related to the study.
SOURCE:
Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. 

Friday, May 17, 2019

Does sleeping on your back cause memory loss?

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Older man, who can̢۪t sleep at night, sitting on bed while spouse sleeps



Could sleeping on your back hurt memory and increase your brain's risk of developing neurodegenerative disease? 




CARLSBAD, Calif.--(BUSINESS WIRE)--Could sleeping on your back increase your brain's risk of developing neurodegenerative disease? That possibility is revealed in a new study published in the Journal of Alzheimer's Disease. 

"We compared the in-home sleep patterns of patients with memory impairment resulting from neurodegenerative diseases to a large group of elderly with normal cognition," stated Daniel J. Levendowski, the study's first author and President of Advanced Brain Monitoring. "Sleeping more than 2 hours with one's head lying face upward (i.e., supine) was a significant nocturnal marker that characterized those with memory impairment, after controlling for factors such as age, sex, snoring, obstructive sleep apnea, and movements during the night."

Supine Sleep + Natural Aging

These results corroborate in humans a finding observed in rats by researchers at Stony Brook University and published in the Journal of Neuroscience. Using dynamic contrast MRI, they found that the clearance of neurotoxic proteins from the brain by glymphatic transport was less efficient when the rats' heads were in the supine sleep position. "Our results clearly support their conclusions," added Dr. Philip Westbrook, Chief Medical Officer of Advanced Brain Monitoring. "We also suggest how the interaction between supine sleep and the natural changes that come with age could impact the clearance of β-amyloid, tau, alpha-synuclein, and other neurotoxins from the brain during sleep."

Strong Association, Potentially Modifiable

Because imaging of the lymphatic system in humans is not yet possible, additional research is needed to establish a causal relationship between neurodegenerative disease and supine sleep.
"The strength of the association, however, points to a potentially modifiable risk factor for neurodegenerative disease, similar to diet and exercise,"
suggested Dr. Charlene Gamaldo, a co-author and Associate Professor of Neurology at Johns Hopkins University School of Medicine. 

The study results were obtained as part of a $2.5 million multi-site longitudinal study funded by the National Institute of Aging and awarded to Advanced Brain Monitoring. The aim of this ongoing research is to characterize the brain's function during wake and sleep to provide early identification and differentiation between mild cognitive impairment, Alzheimer's, Parkinson’s, and other dementias. 

"This is one of many neurodegenerative disease markers we've identified to predict the likelihood of a dementia subtype, quantifying the progression of the disease, and evaluating efficacy of new treatments,” said Chris Berka, principal investigator for the project and CEO of Advanced Brain Monitoring. 


REFERENCE:
SOURCE:
  • Advanced Brain Monitoring, Inc. is a privately-held neuro-diagnostics device company, specializing in the acquisition and analysis of EEG during wake and sleep. The Company's products are used in clinical trials and in clinical practice to interpret brain function as it relates to early stage neurodegeneration and chronic diseases, and to improve sleep quality and enhance performance. Since 2013, the Company has been awarded 15 patents, which includes seven FDA-cleared and CE-marked products. From its inception in 1999, the Company has been awarded over $35 million in government R&D funding.

Wednesday, May 1, 2019

How to keep those with dementia physically active

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two



Sit and Be Fit - Season Eight

SOURCE:
National Institute on Aging
National Institutes of Health
U.S. Department of Health & Human Services
Go4Life is a registered trademark of the U.S. Department of Health and Human Services.

ACTIVITIES FOR ANY DAY - 6 HEALTHY TIPS to help you stay active with Alzheimer's, along with physical activities to do. 



Caregivers can help people with dementia be more active and stay safe:

  1. Be realistic about how much activity can be done at one time. Several 10-minute "mini-workouts" may be best.
  2. Help get the activity started or join in to make the activity more fun.
  3. Find time in the morning for exercise.
  4. Break exercises into simple, easy-to-follow steps.
  5. Choose comfortable clothes that are suitable for the weather and appropriate shoes that fit well.
  6. Make sure both you and the person with dementia drink plenty of water when exercising.

Some physical activities to try:

  • Take a walk together.
  • Do simple tasks around the house, such as sweeping and raking.
  • Work in the garden.
  • Play music and dance.
  • Exercise with videos made for older people. Try the sample workout on NIA's free Go4Life DVD.
  • Throw a soft rubber exercise ball back and forth.
  • Lift weights or household items such as soup cans.
  • Use resistance bands, which you can buy in sporting goods stores. Be sure to follow the instructions.

Quick Tip

Try being active together. Physical activity and exercise are good for caregivers, too!

Visit:

www.nia.nih.gov/Go4Life
  • Read more tips for adding physical activity to your day.
  • Print useful tools.
  • Order a free exercise DVD.
  • Share your exercise story.
Go4Life: 
Everyday Fitness Ideas from the National Institute on Aging at NIH
Helping People with Dementia Disease Stay Physically Active




SOURCE:
National Institute on Aging
National Institutes of Health
U.S. Department of Health & Human Services
Go4Life is a registered trademark of the U.S. Department of Health and Human Services.
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info